$4.40
1.15% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US76200L3096
Symbol
RZLT

Rezolute Inc Stock price

$4.40
+0.67 17.96% 1M
-0.24 5.17% 6M
-0.50 10.20% YTD
-1.08 19.71% 1Y
-2.48 36.00% 5Y
-85.60 95.11% 10Y
-27.10 86.03% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
+0.05 1.15%
ISIN
US76200L3096
Symbol
RZLT

Key metrics

Market capitalization $376.29m
Enterprise Value $289.40m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.23
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-77.04m
Free Cash Flow (TTM) Free Cash Flow $-65.08m
Cash position $86.89m
EPS (TTM) EPS $-1.04
P/E forward negative
Short interest 6.32%
Show more

Is Rezolute Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Rezolute Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Rezolute Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Rezolute Inc forecast:

Buy
100%

Financial data from Rezolute Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 17 17
24% 24%
-
- Research and Development Expense 60 60
26% 26%
-
-77 -77
26% 26%
-
- Depreciation and Amortization 0.03 0.03
25% 25%
-
EBIT (Operating Income) EBIT -77 -77
26% 26%
-
Net Profit -73 -73
26% 26%
-

In millions USD.

Don't miss a Thing! We will send you all news about Rezolute Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rezolute Inc Stock News

Neutral
GlobeNewsWire
16 days ago
Target enrollment exceeded with 62 participants enrolled, including approximately 15 percent from U.S. sites Topline data is anticipated in December of 2025 REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced that enro...
Neutral
GlobeNewsWire
about one month ago
sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025
Neutral
GlobeNewsWire
about one month ago
Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by HI, today ann...
More Rezolute Inc News

Company Profile

Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

Head office United States
CEO Nevan Elam
Employees 55
Founded 2010
Website www.rezolutebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today